Resverlogix Corp. is a clinical-stage cardiovascular company. The Company is developing small molecules that selectively inhibit Bromodomain and ExtraTerminal domain (BET) proteins. Its lead drug compound is RVX-208 (apabetalone). RVX-208 is a small molecule targeted for the treatment of atherosclerosis via the reduction of major adverse cardiovascular events (MACE), and also for treatment of diabetes mellitus (DM), chronic kidney disease (CKD) and Alzheimer's disease (AD). RVX-208 is an oral agent in the BET inhibitor class that targets bromodomain 2 (BD2) of BET protein4 (BRD4) by regulating gene activities. RVX-208 has anti-inflammatory effects, including effects on Interleukin-6 inhibition, vascular cell adhesion-1 and monocyte chemotactic protein-1, complement, factors involved in atherosclerosis and vascular risk. The Company has initiated a Phase III clinical trial BETonMACE with RVX-208 for cardiovascular disease patients with DM and low high-density lipoprotein (HDL).